About BPL

BPL has a 60-year heritage producing plasma products

  • BPL has been producing coagulation products since the 1960s
  • 100% of the plasma used to make COAGADEX is sourced from over 32 corporate-owned collection centers in the United States
  • All plasma centers are FDA inspected and licensed

    BPL Plasma Collection Centers

    BPL Plasma Collection Centers


    • Hot Springs
    • Jonesboro
    • Little Rock
    • Texarkana


    • Flagstaff


    • Gainesville
    • Jacksonville
    • Orlando
    • Temple Terrace


    • Carbondale


    • Bowling Green


    • Lewiston


    • Duluth

    North Carolina

    • Greenville
    • Wilmington

    New Mexico

    • Albuquerque
    • Farmington
    • Gallup
    • Las Cruces


    • Stillwater


    • Austin
    • Beaumont
    • Bryan
    • College Station
    • Lubbock
    • San Angelo
    • San Marcos
    • Wichita Falls

Click here for a list of BPL Plasma Collection Centers

Indications for COAGADEX

COAGADEX, a plasma-derived blood coagulation factor X concentrate, is indicated in adults and children (aged 12 years and above) with hereditary factor X deficiency for:

Perioperative management of bleeding in major surgery in patients with moderate and severe hereditary factor X deficiency has not been studied.

Important Safety Information for COAGADEX

COAGADEX is contraindicated in patients with known hypersensitivity to any of the components of the product.

Allergic type hypersensitivity reactions, including anaphylaxis, are possible with COAGADEX. If symptoms occur, patients should discontinue use of the product immediately and contact their physician.

The formation of neutralizing antibodies (inhibitors) to factor X is a possible complication in the management of individuals with factor X deficiency. Carefully monitor patients taking COAGADEX for the development of inhibitors by appropriate clinical observations and laboratory tests.

COAGADEX is made from human plasma and may contain infectious agents, e.g. viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. No cases of transmission of viral diseases, vCJD or CJD, have been associated with the use of COAGADEX.

In clinical studies, the most common adverse reactions (frequency ‚Č•5% of subjects) with COAGADEX were infusion site erythema, infusion site pain, fatigue and back pain.

Please see complete Prescribing Information for COAGADEX.